These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

352 related items for PubMed ID: 7405678

  • 1. Plasma fluphenazine levels by radioimmunoassay in schizophrenic patients treated with depot injections of fluphenazine decanoate.
    Wiles DH, Gelder MG.
    Adv Biochem Psychopharmacol; 1980; 24():599-602. PubMed ID: 7405678
    [No Abstract] [Full Text] [Related]

  • 2. Plasma fluphenazine levels by radioimmunoassay in schizophrenic patients treated with depot injections of fluphenazine decanoate.
    Wiles DH, Gelder MG.
    Br J Clin Pharmacol; 1979 Dec; 8(6):565-70. PubMed ID: 533577
    [Abstract] [Full Text] [Related]

  • 3. Plasma levels of parent drug and metabolites in patients receiving oral and depot fluphenazine.
    Marder SR, Van Putten T, Aravagiri M, Hubbard JW, Hawes EM, McKay G, Midha KK.
    Psychopharmacol Bull; 1989 Dec; 25(3):479-82. PubMed ID: 2626520
    [Abstract] [Full Text] [Related]

  • 4. Plasma levels of neuroleptic in patients receiving depot fluphenazine.
    Cohen BM, Waternaux C, Chouinard G, Sommer BR, Jones B.
    J Clin Psychopharmacol; 1985 Dec; 5(6):328-32. PubMed ID: 4066997
    [Abstract] [Full Text] [Related]

  • 5. [Characteristics of the therapeutic action fluphenzaine decanoate (moditen-depot) in schizophrenia].
    Tsutsul'kovskaia MIa, Minsker EI, Panteleeva GP, Mazurskii MB, Pekunova LG.
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1973 Dec; 73(5):753-8. PubMed ID: 4718619
    [No Abstract] [Full Text] [Related]

  • 6. Serum neuroleptic levels and clinical outcome in schizophrenic patients treated with fluphenazine decanoate.
    Brown WA, Silver MA.
    J Clin Psychopharmacol; 1985 Jun; 5(3):143-7. PubMed ID: 3998204
    [Abstract] [Full Text] [Related]

  • 7. Plasma fluphenazine levels measured by high-performance liquid chromatography in patients treated with depot injections.
    Jouen F, Verité P, André D, Colonna L, Boucly P.
    Arzneimittelforschung; 1993 May; 43(5):509-11. PubMed ID: 8328993
    [Abstract] [Full Text] [Related]

  • 8. Radioimmunoassay for 7-hydroxy metabolite of fluphenazine and its application to plasma level monitoring in schizophrenic patients treated long term with oral and depot fluphenazine.
    Aravagiri M, Marder SR, Van Putten T, Hawes EM, McKay G, Midha KK.
    Ther Drug Monit; 1994 Feb; 16(1):21-9. PubMed ID: 8160250
    [Abstract] [Full Text] [Related]

  • 9. Low neuroleptic serum levels in patients receiving fluphenazine decanoate.
    Tune LE, Creese I, Coyle JT, Pearlson G, Snyder SH.
    Am J Psychiatry; 1980 Jan; 137(1):80-2. PubMed ID: 6101523
    [Abstract] [Full Text] [Related]

  • 10. Weight gain and prolactin levels in patients on long-term antipsychotic medication: a double-blind comparative trial of haloperidol decanoate and fluphenazine decanoate.
    Cookson JC, Kennedy NM, Gribbon D.
    Int Clin Psychopharmacol; 1986 Jul; 1 Suppl 1():41-51. PubMed ID: 3549879
    [Abstract] [Full Text] [Related]

  • 11. Relapse in chronic schizophrenics treated with fluphenazine decanoate is associated with low serum neuroleptic levels.
    Jayaram G, Coyle J, Tune L.
    J Clin Psychiatry; 1986 May; 47(5):247-8. PubMed ID: 3700342
    [Abstract] [Full Text] [Related]

  • 12. [Prolonged treatment of schizophrenic psychoses with depot-fluphenazine ("lyogen decanoate")].
    Bohacek N, Mihovilović M.
    Neuropsihijatrija; 1968 May; 16(3):69-73. PubMed ID: 5195835
    [No Abstract] [Full Text] [Related]

  • 13. Plasma fluphenazine levels in patients receiving two doses of fluphenazine decanoate.
    Marder SR, Hubbard JW, Van Putten T, Hawes EM, McKay G, Mintz J, May PR, Midha KK.
    Psychopharmacol Bull; 1986 May; 22(1):264-6. PubMed ID: 3726072
    [No Abstract] [Full Text] [Related]

  • 14. Neuroleptic serum levels measured by radioreceptor assay in patients receiving intramuscular depot neuroleptics. Some preliminary findings.
    Turbott J, Villiger J, Hunter L.
    Br J Psychiatry; 1985 Apr; 146():439-42. PubMed ID: 4016448
    [Abstract] [Full Text] [Related]

  • 15. Discontinuation of oral and depot fluphenazine in schizophrenic patients after one year of continuous medication: a controlled study.
    Levine J, Schooler NR, Severe J, Escobar J, Gelenberg A, Mandel M, Sovner R, Steinbook R.
    Adv Biochem Psychopharmacol; 1980 Apr; 24():483-93. PubMed ID: 6996445
    [No Abstract] [Full Text] [Related]

  • 16. Depot fluphenazine and plasma prolactin.
    Gift T, Plum K, Price M.
    Prog Neuropsychopharmacol Biol Psychiatry; 1985 Apr; 9(4):407-12. PubMed ID: 4070643
    [Abstract] [Full Text] [Related]

  • 17. Plasma levels of fluphenazine decanoate. Effects of site of injection, massage and muscle activity.
    Soni SD, Wiles D, Schiff AA, Bamrah JS.
    Br J Psychiatry; 1988 Sep; 153():382-4. PubMed ID: 3250675
    [Abstract] [Full Text] [Related]

  • 18. Plasma prolactin and fluphenazine concentrations in patients receiving fluphenazine decanoate: stability over injection intervals.
    Norman TR, Marriott PF, Kimber NM, Burrows GD.
    Int Clin Psychopharmacol; 1987 Oct; 2(4):299-305. PubMed ID: 3693869
    [Abstract] [Full Text] [Related]

  • 19. Depot fluphenazine in the prevention of relapse in schizophrenia: evaluation of a treatment regimen [proceedings].
    Schooler NR, Levine J, Severe JB.
    Psychopharmacol Bull; 1979 Apr; 15(2):44-7. PubMed ID: 373006
    [No Abstract] [Full Text] [Related]

  • 20. Fluphenazine plasma levels and clinical response.
    Marder SR, Van Putten T, Aravagiri M, Hawes EM, Hubbard JW, McKay G, Mintz J, Midha KK.
    Psychopharmacol Bull; 1990 Apr; 26(2):256-9. PubMed ID: 2236467
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.